7.94 USD
▼-0.15-1.85%
盘后 7.95 +0.13%
2026-09-15
市值
$1.38B
市盈率
—
EPS
-0.80
股息率
—
52 周区间
2.24 – 12.06
成交量
2.33M
Beta
2.44
目标价
14.40
52W 低 2.2452W 高 12.06
价格走势
公司简介
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket...